Autoimmune Disease and Chronic Inflammation: What IgG Glycans Reveal That Standard Labs Don't

Uncover the hidden connections between IgG glycans and autoimmune diseases. Learn how these biomarkers reveal critical information beyond standard lab results.

Autoimmune diseases (AD) occur when the immune system mistakenly identifies healthy cells as foreign and attacks them. Genetic susceptibility plays a role in who develops these conditions, including rheumatoid arthritis, and some AD are more common in certain populations. But genetics only explains part of the picture. The bigger gap sits in how these conditions get caught. Standard rheumatology labs were built to confirm inflammation once it's already underway, not to flag it while it's still building. That distinction, reactive versus proactive, is the real story behind rheumatoid arthritis inflammation and what IgG glycans can reveal about it.
Want the bigger picture first? Rheumatoid arthritis is just one expression of a much broader process driving how the body ages. Read Chronic Inflammation & Inflammaging: The Hidden Driver of How You Age to see how this same immune drift shows up across nearly every age-related condition.
The diagnostic gap: why standard labs react late
"At the molecular level, glycan changes happen before the disease does. We know these glycans promote inflammation, and we know inflammation correlates with disease development. What we hope is that glycans can act as an intermediate endpoint, something measurable early enough to predict whether a disease can be prevented altogether."
— Prof. Gordan Lauc, Co-Founder and Chief Scientific Officer, GlycanAge; Professor of Biochemistry and Molecular Biology, University of Zagreb
Conventional rheumatoid arthritis workups typically rely on rheumatoid factor, anti-CCP antibodies, and acute phase reactants like CRP and ESR. These markers are useful, but they share a structural limitation: they respond to inflammation that has already reached a clinically significant threshold. CRP and ESR rise once tissue-level inflammation is active; rheumatoid factor and anti-CCP can be negative in a meaningful share of people who go on to develop RA. None of them are designed to pick up the slower, cumulative immune drift that precedes a diagnosis. That gap is part of what standard blood tests miss about hidden inflammation more broadly, and it's the reason interest in glycan analysis as a complementary, earlier-warning layer has grown alongside these established markers rather than in place of them.
The predictive power of IgG glycans
There is now mounting evidence for the role of glycans in autoimmunity. Glycans are sugar molecules that surround and modify proteins in the body, a process known as glycosylation, and this modification can alter how a protein functions. Unlike the genetic code, glycans are heavily influenced by environmental conditions, diet, and lifestyle factors like stress, meaning there is some degree of control over how glycans affect immune function.
Antibodies are proteins produced by immune cells that normally protect against infection, but in autoimmune disease they can turn against the body's own proteins. In landmark research, scientists discovered that the glycan structures attached to IgG antibodies were altered in patients with rheumatoid arthritis and primary osteoarthritis, one of the earliest pieces of evidence linking glycosylation to joint disease. Specifically, IgG in people with rheumatoid arthritis tends to carry fewer galactose sugars on its glycan structures, a change known as agalactosylation. This shift isn't cosmetic: it changes how the antibody interacts with immune receptors, and agalactosylated IgG is more capable of triggering pro-inflammatory pathways, including complement activation, that contribute to joint damage.
This is where the proactive-versus-reactive distinction becomes concrete. Long-term follow-up research has shown that low IgG galactosylation is associated with a higher risk of a future rheumatoid arthritis diagnosis, with the glycan shift detectable well before clinical symptoms or standard lab abnormalities appear. This has since been shown to extend to several other autoimmune diseases, each with its own distinct pattern of glycan changes on antibodies, an idea formalized as the "Altered Glycan Theory" of autoimmunity.
"We have evidence that a switch in the glycosylation profile of B cells occurs before the development of autoimmune diseases such as rheumatoid arthritis. We want to understand when, why, and how that switch happens, and the mechanism behind it. By preventing the glycan switch, we could potentially prevent rheumatoid arthritis from developing at all, and intercept the disease before it starts."
— Prof. Salomé Pinho, Immunology, Cancer and Glyco Medicine Group Leader, i3S – Institute for Research and Innovation in Health, University of Porto
Standard labs vs. IgG glycans
These two approaches aren't interchangeable, and understanding the difference is the point:
Standard Labs (CRP, ESR, RF, anti-CCP) | IgG Glycans | |
What it measures | Acute phase reactants and disease-specific antibodies | Long-term structural changes in antibody glycosylation |
Timing | Reactive, rises after inflammation is already active | Proactive, shifts can precede clinical onset |
Sensitivity to low-grade inflammation | Limited; can miss chronic, sub-threshold activity | Designed to reflect cumulative immune-system state |
Response to intervention | Can fluctuate quickly with acute changes | Shifts over months as the underlying immune trajectory changes |
Best used for | Confirming and staging active disease | Monitoring systemic inflammatory burden over time |
Biological age vs. chronological age: measuring the inflammatory burden standard panels ignore
This is the same biological signal that GlycanAge measures. GlycanAge is an at-home biological age test that analyzes IgG glycosylation from a simple finger-prick blood sample, reflecting immune function and chronic inflammation, sometimes called "inflammaging," rather than the DNA-based signals used by epigenetic clocks. Because standard panels are built around chronological milestones and acute-phase snapshots, they have no real mechanism for capturing systemic inflammatory burden as it accumulates. Glycan-based biological age testing fills that gap: it reflects how much cumulative immune strain the body is carrying, independent of age on paper.
Actionable insight: pre-symptomatic lifestyle interventions
Because glycan shifts can appear before a diagnosis is on the table, tracking them creates room to act earlier rather than later. Someone with a family history of rheumatoid arthritis, or early joint discomfort that hasn't yet produced abnormal standard labs, can use a change in their glycan profile as a cue to address diet, stress, sleep, and activity levels while the underlying immune drift is still in its early, more modifiable stages.
"Rheumatoid arthritis involves auto-antibodies that attack collagen in the joints, and it's very much associated with sex hormones. What we found in our research is that women with rheumatoid arthritis who become pregnant see their antibodies turn more anti-inflammatory, and their symptoms decrease. Those women still have the same auto-antibodies throughout, but the glycosylation on those antibodies is the factor that changes. It shifts from pro-inflammatory to anti-inflammatory during pregnancy, and back again once estrogen and progesterone levels drop."
— Dr. Julija Jurić, Lead Author, Genos Glycoscience Research Laboratory
For someone already managing rheumatoid arthritis, the same signal works in the other direction: a DMARD or biologic that's working should, over time, be calming the same immune-inflammatory processes reflected in IgG glycosylation, and retesting after starting or adjusting a pharmaceutical intervention gives that change time to show up. Lifestyle-driven approaches tend to shift more gradually and are generally better assessed over a longer stretch of time. Readers exploring at-home options for their own tracking can find more detail on the personal use page.
For clinicians: adding an immune aging layer to RA management
For rheumatologists and functional medicine practitioners, the value of glycan analysis isn't that it replaces rheumatoid factor, anti-CCP, or imaging, it's that it adds a continuous, proactive measure of immune-related biological aging that standard reactive markers can't provide on their own. Because IgG glycosylation responds within months rather than years, it offers a way to see whether a treatment plan is meaningfully shifting a patient's underlying inflammatory trajectory, not just their symptom scores at a single visit. Practices interested in incorporating this kind of testing into patient monitoring can learn more on the healthcare providers page.
Rheumatoid arthritis inflammation doesn't announce itself the moment standard labs can see it. The data shows the immune shift starts well before that point, and glycan analysis is one of the few tools built to read it early rather than after the fact.
See where your own immune system stands. A GlycanAge test measures the same IgG glycosylation signal discussed throughout this article, giving you a clear, trackable baseline before symptoms, not after.
Shop GlycanAge tests to get started.
External sources
https://www.nature.com/articles/316452a0 — Parekh RB, Dwek RA, Sutton BJ, Fernandes DL, Leung A, Stanworth D, et al. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature. 1985;316(6027):452-7.
https://www.nature.com/articles/nm0395-237 — Malhotra R, Wormald MR, Rudd PM, Fischer PB, Dwek RA, Sim RB. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat Med. 1995;1(3):237-43.
https://www.sciencedirect.com/science/article/pii/S092544391830098X?via%3Dihub — Gudelj I, Salo PP, Trbojević-Akmačić I, Albers M, Primorac D, Perola M, et al. Low galactosylation of IgG associates with higher risk for future diagnosis of rheumatoid arthritis during 10 years of follow-up. Biochim Biophys Acta Mol Basis Dis. 2018;1864(6 Pt A):2034-9.
https://pubmed.ncbi.nlm.nih.gov/20506563/ — Ercan A, Cui J, Chatterton DE, Deane KD, Hazen MM, Brintnell W, et al. Aberrant IgG galactosylation precedes disease onset, correlates with disease activity, and is prevalent in autoantibodies in rheumatoid arthritis. Arthritis Rheum. 2010;62(8):2239-48.
https://www.sciencedirect.com/science/article/pii/S0896841114001759?via%3Dihub — Maverakis E, Kim K, Shimoda M, Gershwin ME, Patel F, Wilken R, et al. Glycans in the immune system and The Altered Glycan Theory of Autoimmunity: a critical review. J Autoimmun. 2015;57:1-13.
https://pubmed.ncbi.nlm.nih.gov/17847113/ — Croce A, Firuzi O, Altieri F, Eufemi M, Agostino R, Priori R, et al. Effect of infliximab on the glycosylation of IgG of patients with rheumatoid arthritis. J Clin Lab Anal. 2007;21(5):303-14.
https://pubmed.ncbi.nlm.nih.gov/19035662/ — Knežević A, Polašek O, Gornik O, Rudan I, Campbell H, Hayward C, et al. Variability, heritability and environmental determinants of human plasma N-glycome. J Proteome Res. 2009;8(2):694-701.
https://pmc.ncbi.nlm.nih.gov/articles/PMC12821548/ — Lhotellerie F, Ben Ismail AE, Sarrand J, Soyfoo M. Seronegative Rheumatoid Arthritis: A Distinct Immunopathological Entity with Erosive Potential. Med Sci (Basel). 2025;14(1):14.

Turn health content into action
Explore biological age testing for immune health and inflammaging, GlycanAge for personal wellness tracking, and ordering a GlycanAge biological age test.

The Future of Healthcare is Preventative, Personalised, and Powered by Glycans
Whether you’re improving your own health, supporting patients, or driving research, GlycanAge helps you turn science into action.

Glycans and Brain Health: The Sugar-Cognition Connection Behind Neurodegeneration
Explore the intricate relationship between glycans and brain health, uncovering how sugar impacts cognition and contributes to neurodegeneration.
November 19, 2026
10 minutes

Can You Rebuild a Younger Immune System?
Learn how glycan biomarkers show measurable immune-age reduction from lifestyle and medical interventions, with real repeat-testing data.
November 17, 2026
10 minutes